Clinical Trial Update: A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias [Phase 1]

View source ↗

Summary

Phase I pediatric trial of cladribine, low-dose cytarabine, and sorafenib alternating with decitabine for relapsed or refractory acute leukemia has been withdra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• Cladribine (cladribine)
• Cytarabine (Low-Dose) (cytarabine)
• Decitabine (Decitabine)
• Sorafenib (Sorafenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Refractory Acute Leukemia, Relapsed Acute Leukemia | Phase 1 | Status: WITHDRAWN